PECAM-1 is required for transendothelial migration of leukocytes.

TLDR

PECAM‑1 (CD31) is essential for leukocyte transendothelial migration across endothelial junctions, a step distinct from rolling and adhesion. Blocking PECAM‑1 with antibody or soluble protein inhibits monocyte and neutrophil transendothelial migration by 70–90 % without affecting chemotaxis, and microscopy shows cells remain adherent at intercellular junctions.

Abstract

Platelet/endothelial cell adhesion molecule 1 (PECAM-1; CD31) is crucial to the process of leukocyte transmigration through intercellular junctions of vascular endothelial cells. A monoclonal antibody to PECAM, or recombinant soluble PECAM, blocks transendothelial migration of monocytes by 70-90%. Pretreating either the monocytes or the endothelial junctions with antibody blocks transmigration. If the endothelium is first activated by cytokines, anti-PECAM antibody or soluble recombinant PECAM again block transmigration of both monocytes and neutrophils. Anti-PECAM does not block chemotaxis of either cell type. Light and electron microscopy reveal that leukocytes blocked in transmigration remain tightly bound to the apical surface of the endothelial cell, precisely over the intercellular junction. Thus, the process of leukocyte emigration can be dissected into three successive stages: rolling, mediated by the selectin class of adhesion molecules; tight adhesion, mediated by the leukocyte integrins and their endothelial cell counter-receptors; and now transmigration, which, based on these studies, requires PECAM-1.